Higher THC Concentration Medicinal Cannabis Products Efficacy and Safety Considerations: A Rapid Review
Drug and Alcohol Review · 2026-05 · 45 (4)
DOI: 10.1111/dar.70145 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug and Alcohol Review, online erschienen am 01.04.2026. Verfasst von Myfanwy Graham und 3 weiteren Autor:innen. Beteiligte Einrichtung: Monash Addiction Research Centre, Eastern Health Clinical School, Monash University, Melbourne, Australia. Hauptthemen laut MEDLINE: Dronabinol, Medical Marijuana. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Department of Health, Disability and Ageing, Australian Government, Department of Health, Disability and Ageing.
Abstract (Originalsprache)
Issues Higher delta‐9‐tetrahydrocannabinol (THC) concentration medicinal cannabis products are characterised by a higher THC and minimal cannabidiol (CBD) content. This rapid review aims to systematically summarise and evaluate the available evidence regarding the efficacy and safety of higher THC potency medicinal cannabis products relevant to the Australian market in adult populations. Approach The rapid literature review protocol was prospectively registered with Open Science Framework: https://doi.org/10.17605/OSF.IO/HNFUT . The comprehensive search (1‐January‐2014–30‐July‐2024) included Medline, EMBASE, EMCARE, CINAHL, SCOPUS and the Cochrane Central Register of Controlled Trials databases. Eligible studies (randomised controlled trials and observational studies) were screened by two independent reviewers and then extracted. Key Findings We identified 9969 records, resulting in 15 studies (six RCTs and nine observational), with THC concentrations of 16%–22% that met inclusion criteria. Studies examining efficacy for pain ( n = 4), ulcerative colitis ( n = 1) and chronic obstructive pulmonary disease ( n = 1) reported mixed outcomes. Reported adverse events included psychiatric, nervous system and gastrointestinal effects. Validated cannabis use disorder (CUD) screening tools were notably absent from the included studies.
Implications
Few studies have assessed products equivalent to the Australian Category 5 medicinal cannabis product definition, with most having THC concentrations lower than those available for prescription in Australia, including products reported to contain up to 88% THC. High‐quality RCTs and longitudinal studies that incorporate validated CUD screening tools are needed.
Conclusion
No evidence was found on safety or efficacy of prescribed Category 5 medicinal cannabis products with THC concentrations above 22% w/w (220 mg/g).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Monash Addiction Research Centre, Eastern Health Clinical School, Monash University, Melbourne, Australia.
- Monash Sustainable Development Institute Evidence Review Service, Monash University, Melbourne, Australia.
ORCID-Profile: Myfanwy Graham, Suzanne Nielsen
Förderung
- National Health and Medical Research Council
- Department of Health, Disability and Ageing, Australian Government
- Department of Health, Disability and Ageing
Zitieren
APA
Graham, M., Assefa, D., Cong-Lem, N., & Nielsen, S. (2026). Higher THC Concentration Medicinal Cannabis Products Efficacy and Safety Considerations: A Rapid Review. Drug and Alcohol Review, 45(4). https://doi.org/10.1111/dar.70145
Vancouver
Graham M, Assefa D, Cong-Lem N, Nielsen S. Higher THC Concentration Medicinal Cannabis Products Efficacy and Safety Considerations: A Rapid Review. Drug and Alcohol Review. 2026;45(4). doi:10.1111/dar.70145
BibTeX
@article{Graham2026,
author = {Graham, Myfanwy and Assefa, Dereje and Cong-Lem, Ngo and Nielsen, Suzanne},
title = {Higher THC Concentration Medicinal Cannabis Products Efficacy and Safety Considerations: A Rapid Review},
journal = {Drug and Alcohol Review},
year = {2026},
volume = {45},
number = {4},
doi = {10.1111/dar.70145}
}
EUVIMED